| Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma JJ Keats, R Fonseca, M Chesi, R Schop, A Baker, WJ Chng, S Van Wier, ... Cancer cell 12 (2), 131-144, 2007 | 1211 | 2007 |
| Clonal competition with alternating dominance in multiple myeloma JJ Keats, M Chesi, JB Egan, VM Garbitt, SE Palmer, E Braggio, ... Blood, The Journal of the American Society of Hematology 120 (5), 1067-1076, 2012 | 777 | 2012 |
| Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia TD Shanafelt, XV Wang, NE Kay, CA Hanson, S O’Brien, J Barrientos, ... New England Journal of Medicine 381 (5), 432-443, 2019 | 738 | 2019 |
| Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide YX Zhu, E Braggio, CX Shi, LA Bruins, JE Schmidt, S Van Wier, XB Chang, ... Blood, The Journal of the American Society of Hematology 118 (18), 4771-4779, 2011 | 682 | 2011 |
| Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides JB Egan, CX Shi, W Tembe, A Christoforides, A Kurdoglu, S Sinari, ... Blood, The Journal of the American Society of Hematology 120 (5), 1060-1066, 2012 | 503 | 2012 |
| Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL W Ding, BR LaPlant, TG Call, SA Parikh, JF Leis, R He, TD Shanafelt, ... Blood, The Journal of the American Society of Hematology 129 (26), 3419-3427, 2017 | 414 | 2017 |
| Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma O Zavidij, NJ Haradhvala, TH Mouhieddine, R Sklavenitis-Pistofidis, S Cai, ... Nature cancer 1 (5), 493-506, 2020 | 248 | 2020 |
| Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas G Vasmatzis, SH Johnson, RA Knudson, RP Ketterling, E Braggio, ... Blood, The Journal of the American Society of Hematology 120 (11), 2280-2289, 2012 | 246 | 2012 |
| Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes KM Kortüm, EK Mai, NH Hanafiah, CX Shi, YX Zhu, L Bruins, S Barrio, ... Blood, The Journal of the American Society of Hematology 128 (9), 1226-1233, 2016 | 232 | 2016 |
| Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma YX Zhu, E Braggio, CX Shi, KM Kortuem, LA Bruins, JE Schmidt, ... Blood, The Journal of the American Society of Hematology 124 (4), 536-545, 2014 | 231 | 2014 |
| Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas E Braggio, S Van Wier, J Ojha, E McPhail, YW Asmann, J Egan, ... Clinical Cancer Research 21 (17), 3986-3994, 2015 | 219 | 2015 |
| BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies JM Bogenberger, SM Kornblau, WE Pierceall, R Lena, D Chow, CX Shi, ... Leukemia 28 (8), 1657-1665, 2014 | 206 | 2014 |
| Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-κB signaling pathways in Waldenstrom's macroglobulinemia E Braggio, JJ Keats, X Leleu, S Van Wier, VH Jimenez-Zepeda, R Valdez, ... Cancer research 69 (8), 3579-3588, 2009 | 189 | 2009 |
| Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276 J Schmidt, E Braggio, KM Kortuem, JB Egan, YX Zhu, CS Xin, ... Leukemia 27 (12), 2357-2365, 2013 | 170 | 2013 |
| High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma A Miller, Y Asmann, L Cattaneo, E Braggio, J Keats, D Auclair, S Lonial, ... Blood cancer journal 7 (9), e612-e612, 2017 | 148 | 2017 |
| The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition WJ Chng, E Braggio, G Mulligan, B Bryant, E Remstein, R Valdez, ... Blood, The Journal of the American Society of Hematology 111 (3), 1603-1609, 2008 | 145 | 2008 |
| Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016 P Kapoor, SM Ansell, R Fonseca, A Chanan-Khan, RA Kyle, SK Kumar, ... JAMA oncology 3 (9), 1257-1265, 2017 | 138 | 2017 |
| MYC dysregulation in the progression of multiple myeloma K Misund, N Keane, CK Stein, YW Asmann, G Day, S Welsh, SA Van Wier, ... Leukemia 34 (1), 322-326, 2020 | 133 | 2020 |
| RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5 YX Zhu, R Tiedemann, CX Shi, H Yin, JE Schmidt, LA Bruins, JJ Keats, ... Blood, The Journal of the American Society of Hematology 117 (14), 3847-3857, 2011 | 132 | 2011 |
| Precancer atlas to drive precision prevention trials A Spira, MB Yurgelun, L Alexandrov, A Rao, R Bejar, K Polyak, ... Cancer research 77 (7), 1510-1541, 2017 | 128 | 2017 |
